Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thoracic cancers

1036 - Prognostic significance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy


19 Dec 2015


Thoracic cancers


Norikazu Matsuo


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


N. Matsuo, T. Tokito, K. Azuma, H. Ishii, K. Yamada, T. Hoshino

Author affiliations

  • Division Of Respirology, Neurology, And Rheumatology, Department Of Internal Medicine, Kurume University, 830-0011 - Kurume/JP

Abstract 1036


Previous studies of patients with recurrent cancer have indicated that clinical responses to immune checkpoint blockers are associated with elevated tumor levels of programmed cell death-ligand 1 (PD-L1) and increased numbers of tumor-infiltrating lymphocytes (TILs). We investigated the prognostic significance of PD-L1 expression and CD8+ TIL density in patients with locally advanced non-small cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy (CCRT).


We retrospectively reviewed 74 consecutive patients with stage III NSCLC who had received CCRT. PD-L1 expression and CD8+ TIL density were evaluated by immunohistochemical analysis.


PD-L1+ patients showed shorter progression-free survival (PFS) and overall survival (OS) than PD-L1- patients (10.8 versus 17.3 months; p = 0.73, 24.9 vs 36.9 months; p = 0.85; respectively). Univariate and multivariate analyses demonstrated that CD8+ TIL density was an independent and significant predictive factor for PFS and OS. Sub-analysis revealed that the PD-L1 + /CD8 low group had the shortest PFS (8.6 months, p = 0.024) and OS (13.9 months, p = 0.105), and that the PD-L1-/CD8 high group had the longest prognosis (median PFS and OS were not reached) among the four sub-groups.


Among stage III NSCLC patients who received CCRT, there was a trend for poor survival in those who expressed PD-L1. Our analysis indicated that a combination of PD-L1 expression and CD8+ TIL density was significantly associated with favorable survival in these patients. It is proposed that PD-L1 expression in combination with CD8+ TIL density could be a useful predictive biomarker in patients with stage III NSCLC.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings